Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Disorders of Hemostasis01:24

Disorders of Hemostasis

1.6K
Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
1.6K
Extrinsic and Intrinsic Pathways of Hemostasis01:20

Extrinsic and Intrinsic Pathways of Hemostasis

10.6K
Blood clotting or coagulation involves extrinsic and intrinsic pathways, which ultimately merge into the common pathway, forming a fibrin clot.
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
10.6K
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

1.2K
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
1.2K
Clot Retraction and Fibrinolysis01:16

Clot Retraction and Fibrinolysis

7.7K
After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.
7.7K
Coagulation01:09

Coagulation

8.7K
The coagulation phase is a critical part of the body's process to prevent blood loss following injury to blood vessels. It involves chemical reactions that form a clot to seal the injured area. The clotting process begins shortly after injury, within 15-20 seconds for severe damage and 1-2 minutes for minor injuries.
During the coagulation phase, clotting factors, or procoagulants, play a vital role in initiating and progressing the coagulation cascade. This cascade is a series of reactions...
8.7K
Coagulation01:06

Coagulation

595
Colloidal solids are solid particles suspended in solution. They are usually negatively charged, attracting a compact primary layer of positively charged ions, which attract more counterions to form an electrical double layer. Electrostatic repulsion between the charged double layers prevents the particles from colliding, stabilizing the colloids. These solids are often undesirable because they can contain toxins that are difficult to remove. Coagulation is a technique that helps aggregate and...
595

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Relative importance of weight gain among cardiometabolic risk factors in the development of metabolic dysfunction-associated steatotic liver disease: An observational study using large-scale health examination data.

Internal medicine (Tokyo, Japan)·2026
Same author

Association Between Locomotive Syndrome and N-Terminal Pro B-Type Natriuretic Peptide Concentration in a Health Screening Cohort: A Retrospective Cross-Sectional Study.

Circulation reports·2026
Same author

An exploratory plasma-based functional assay for phenotypic characterization of fibrinolysis in dysfibrinogenemia.

Research and practice in thrombosis and haemostasis·2026
Same author

Spatiotemporal dynamics and ossification of podoplanin-positive cells in the developing femur.

Scientific reports·2026
Same author

Association Between Periodontitis and Metabolic Dysfunction-Associated Steatotic Liver Disease: A Cross-Sectional Study.

Clinical and experimental dental research·2026
Same author

Longitudinal change in anterior chamber depth and its determinants: a median 4.9-year follow-up of 2,247 Japanese adults.

Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie·2026

Related Experiment Video

Updated: Nov 12, 2025

Measurement of Factor V Activity in Human Plasma Using a Microplate Coagulation Assay
13:08

Measurement of Factor V Activity in Human Plasma Using a Microplate Coagulation Assay

Published on: September 9, 2012

19.2K

Unrecognized blood clotting factors.

Hidehiko Saito1, Tetsuhito Kojima2

  • 1National Hospital Organization Nagoya Medical Center, 4-1-1 Sanno-maru, Naka-ku, Nagoya, 460-0001, Japan. hi.saito@nnh.hosp.go.jp.

International Journal of Hematology
|March 20, 2021
PubMed
Summary

This review examines unapproved clotting factors, clarifying their identities to prevent confusion in coagulation disorder research. It aims to distinguish these factors from already identified ones.

Keywords:
BleedingClotting factorCoagulation disorder

More Related Videos

Leveraging Turbidity and Thromboelastography for Complementary Clot Characterization
06:28

Leveraging Turbidity and Thromboelastography for Complementary Clot Characterization

Published on: June 4, 2020

7.0K
A Microfluidic Flow Chamber Model for Platelet Transfusion and Hemostasis Measures Platelet Deposition and Fibrin Formation in Real-time
09:38

A Microfluidic Flow Chamber Model for Platelet Transfusion and Hemostasis Measures Platelet Deposition and Fibrin Formation in Real-time

Published on: February 14, 2017

14.1K

Related Experiment Videos

Last Updated: Nov 12, 2025

Measurement of Factor V Activity in Human Plasma Using a Microplate Coagulation Assay
13:08

Measurement of Factor V Activity in Human Plasma Using a Microplate Coagulation Assay

Published on: September 9, 2012

19.2K
Leveraging Turbidity and Thromboelastography for Complementary Clot Characterization
06:28

Leveraging Turbidity and Thromboelastography for Complementary Clot Characterization

Published on: June 4, 2020

7.0K
A Microfluidic Flow Chamber Model for Platelet Transfusion and Hemostasis Measures Platelet Deposition and Fibrin Formation in Real-time
09:38

A Microfluidic Flow Chamber Model for Platelet Transfusion and Hemostasis Measures Platelet Deposition and Fibrin Formation in Real-time

Published on: February 14, 2017

14.1K

Area of Science:

  • Hematology
  • Biochemistry
  • Medical Genetics

Background:

  • Clotting factors were historically identified through rare hereditary coagulation disorders.
  • Inconsistent naming conventions arose, leading to the same factors having multiple names.
  • An international committee was established to standardize clotting factor nomenclature.

Purpose of the Study:

  • To review clotting factors lacking official authorization.
  • To determine if these unapproved factors are identical to known clotting factors.

Main Methods:

  • Literature review of historical and current research on clotting factor nomenclature.
  • Analysis of functional and biochemical data for unapproved clotting factors.
  • Comparison of characteristics of unapproved factors with established clotting factors.

Main Results:

  • Several clotting factors remain unassigned or lack official authorization.
  • Preliminary analysis suggests some unapproved factors may be distinct entities.
  • Further investigation is needed to definitively characterize these factors.

Conclusions:

  • Standardizing clotting factor nomenclature is crucial for clear scientific communication.
  • Clarifying the identity of unapproved factors will aid in understanding coagulation pathways.
  • This review highlights the ongoing need for nomenclature refinement in hematology.